Q3 EPS Estimates for Eton Pharmaceuticals Raised by B. Riley

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley boosted their Q3 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research note issued on Wednesday, July 16th. B. Riley analyst M. El-Saadi now expects that the company will earn $0.16 per share for the quarter, up from their previous estimate of $0.15. B. Riley has a "Buy" rating and a $26.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q4 2025 earnings at $0.42 EPS, FY2026 earnings at $1.06 EPS and FY2027 earnings at $1.74 EPS.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 3.15% and a negative net margin of 9.49%. The company had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price (up previously from $33.00) on shares of Eton Pharmaceuticals in a research report on Thursday, May 29th. Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th.

Eton Pharmaceuticals Stock Up 7.7%

NASDAQ ETON traded up $1.07 during mid-day trading on Friday, reaching $15.02. The stock had a trading volume of 443,620 shares, compared to its average volume of 275,769. Eton Pharmaceuticals has a 1 year low of $3.25 and a 1 year high of $21.48. The stock has a market cap of $402.81 million, a PE ratio of -83.44 and a beta of 1.18. The company has a fifty day moving average price of $16.14 and a 200 day moving average price of $15.31. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.97 and a quick ratio of 1.43.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. increased its holdings in Eton Pharmaceuticals by 18.3% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock valued at $141,000 after buying an additional 1,634 shares in the last quarter. XTX Topco Ltd increased its holdings in Eton Pharmaceuticals by 29.6% in the fourth quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock valued at $195,000 after buying an additional 3,351 shares in the last quarter. AlphaQuest LLC purchased a new position in Eton Pharmaceuticals in the first quarter valued at $53,000. Tower Research Capital LLC TRC purchased a new position in Eton Pharmaceuticals in the fourth quarter valued at $86,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Eton Pharmaceuticals in the first quarter valued at about $101,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 10,223 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $14.73, for a total value of $150,584.79. Following the transaction, the insider directly owned 612,646 shares in the company, valued at $9,024,275.58. This represents a 1.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 34,000 shares of company stock valued at $504,318. Corporate insiders own 16.03% of the company's stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.